---
document_datetime: 2025-09-05 15:58:57
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hemlibra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: hemlibra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.5286376
conversion_datetime: 2025-12-29 20:20:40.134342
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Hemlibra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10668 /202311  | Periodic Safety Update EU Single assessment - emicizumab                                                                                      | 13/06/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IB/0042              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 27/05/2024                          | n/a                                         |                                  |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0040   | B.IV.1.z - Change of a measuring or administration device - Other variation                                                                                                                                                              | 20/02/2024   | 20/02/2025   | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0037   | B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products | 09/11/2023   | 16/02/2024   | SmPC, Labelling and PL | Annex I has been updated to include the new presentation in the qualitative and quantitative composition section as follows: Each vial of 0.4 mL contains 12 mg of emicizumab at a concentration of 30 mg/mL. To include nature and content of container as follows: 3 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film and crimped with an aluminium cap fitted with a plastic flip-off disk. Each vial contains 12 mg emicizumab in 0.4 mL of solution for injection. Each carton contains one vial. To include marketing authorization section as follows: Hemlibra 30 mg/mL solution for injection EU/1/18/1271/006 (12 mg/0.4 mL) The Labelling and PL have been updated accordingly. Enclosure colour used to differentiate the presentations have been added into section 6.5 in line with SmPC guideline. Changes are also made to the Package Leaflet to bring it in line with SmPC and the current QRD template (i.e, inclusion of statement 'Not all pack sizes may be marketed' in section 6). In addition, the list of local representatives in the PL is |
| IB/0039/G | This was an application for a group of variations.                                                                                                                                                                                       | 09/10/2023   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | product - Other changes to a test procedure (including replacement or addition) B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                              |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0038/G | This was an application for a group of variations. A.z - Administrative change - Other variation B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change | 09/10/2023 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                 |            |            |                        |                                                                  |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------|
| IA/0036/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                  | 12/06/2023 | n/a        |                        |                                                                  |
| PSUSA/10668 /202211 | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                                                                                                                                                                                                                        | 08/06/2023 | n/a        |                        | PRAC Recommendation - maintenance                                |
| IA/0035             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                   | 15/05/2023 | 16/02/2024 | Annex II and PL        |                                                                  |
| II/0033             | B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products                                                                                                                                        | 02/03/2023 | 16/02/2024 | SmPC, Labelling and PL |                                                                  |
| II/0027             | Extension of indication to include routine prophylaxis of bleeding episodes in adult and paediatric patients with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have moderate disease (FVIII ≥ 1% and ≤ 5%) with severe b leeding phenotype. Hemlibra can be used in all age groups. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the | 15/12/2022 | 23/01/2023 | SmPC and PL            | Please refer to Scientific Discussion 'Hemlibra-H-C-4406-II- 27' |

<div style=\"page-break-after: always\"></div>

|                     | SmPC and Section 1 of the package leaflet are updated. In addition, Section 4.2 is updated to make it clear that the maintenance dose for Hemlibra applies from week 5 of dosing. The PIL is updated accordingly. Version 4.7 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                          |            |            |                              |                                                                                                                                                                                                                                                                        |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0032              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 21/07/2022 | 15/09/2022 | SmPC, Annex II and Labelling | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Hemlibra in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10668 /202111 | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/06/2022 | n/a        |                              | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| II/0029/G           | This was an application for a group of variations. B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a | 05/05/2022 | 15/09/2022 | Annex II                     | The Annex IIA has been updated to add the following site as a manufacturer of the biological active substance: F. Hoffmann La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0031 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                    | 20/04/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0028 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                             | 10/03/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0025 | Update of sections 4.4, 4.8 and 5.1 of the Product information concerning immunogenicity and loss of efficacy due to anti-emicizumab antibodies. The RMP (v.4.1) is proposed to be updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/03/2022 | 15/09/2022 | SmPC, Labelling and PL | Update of the Product Information and RMP to inform HCPs that unexpected bleeding symptoms while on emicizumab suggest the possibility of an antidrug antibody (with frequency uncommon). This is based on pooled data from 7 Phase III Clinical trials (BH29884, BH29992, BH30071, BO39182, YO39309, JO39881, and MO39129). For more information, please refer to the Summary of Product Characteristics. |
| II/0026 | Update of section 4.8 of the SmPC to include new data related to hypersensitivity, in compliance with the PRAC recommendation following the assessment of PSUSA/00010668/202011. The PIL is updated in accordance with the changes to the SmPC.                                                                           | 28/10/2021 | 15/09/2022 | SmPC and PL            | The product information has been updated to include the following ADRs from postmarketing surveillance: Angioedema (uncommon), urticaria (common) and rash (common)                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0023/G | This was an application for a group of variations. 1. B.I.a.1.g (Type II) - To add Chugai Pharma Manufacturing Co, Ltd, 5-1, Ukima 5-Chrome, Kita- Ku-Tokyo 115-8543, Japan as an alternative site responsible for the manufacturing, testing and storage of the active substance emicizumab. 2. B.I.a.1.f (Type IB) - To add BioReliance Ltd, Todd Campus, West of Scotland Science Park, Glasgow, G20 OXA UK as an alternative in-process control (IPC) testing site responsible for the mycoplasma testing of the preharvest cell culture fluid (PHCCF). 3. B.I.a.1.f (Type IB) - To add Chugai Pharma Manufacturing, Co., Ltd. 116-3, Kiyohara Kogyodanchi, Utsunomiya City, Tochigi 321-3231 Japan (UT) as an alternative in-process control (IPC) testing site responsible for the mycoplasma testing of the preharvest cell culture fluid (PHCCF). 4. B.I.a.1.f (Type IB) - To add Charles River Laboratories, Inc. 466 Devon Park Drive, Wayne, PA 19406 USA as an alternative in-process control (IPC) testing site responsible for the virus testing of the preharvest cell culture fluid (PHCCF). | 16/09/2021 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| the active substance emicizumab Chugai Ukima Building 6000 L. 6. B.I.a.4.c (Type IB) - in-process test for Leptospira manufacture of the active Chugai Ukima Building 7. B.I.c.1.c (Type IB) - composition of the immediate substance emicizumab. In addition, the Marketing (MAH) has taken the opportunity of Module 3. B.I.a.1.g - Change in the starting material/reagent/intermediate Introduction of a new manufacturer not supported by an ASMF update to the relevant B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile)   |            |            |    | B.I.a.1.f - Change in   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-------------------------|
| N/0024  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10/08/2021 | 15/09/2022 | PL |                         |
| II/0021 | Submission of an updated RMP version 2.6 in order to add thromboembolic events without concomitant aPCC as an important potential risk in the safety specifications and to update the milestones for BO40853/SURVEY study following approval of the protocol v3 (via MEA PRO 002.2). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH assessment is required                                            | 08/07/2021 | n/a        |    | where significant       |

<div style=\"page-break-after: always\"></div>

| PSUSA/10668 /202011   | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                                          | 10/06/2021   | n/a        |             | PRAC Recommendation - maintenance   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------|
| PSUSA/10668 /202005   | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                                          | 14/01/2021   | n/a        |             | PRAC Recommendation - maintenance   |
| IB/0020               | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                       | 07/12/2020   | 18/08/2021 | SmPC        |                                     |
| IB/0017               | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking               | 19/08/2020   | 18/08/2021 | SmPC and PL |                                     |
| IB/0018               | B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation                                                                               | 28/07/2020   | n/a        |             |                                     |
| PSUSA/10668 /201911   | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                                          | 11/06/2020   | n/a        |             | PRAC Recommendation - maintenance   |
| IB/0015               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                    | 19/12/2019   | 23/01/2020 | SmPC        |                                     |
| PSUSA/10668 /201905   | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                                          | 28/11/2019   | n/a        |             | PRAC Recommendation - maintenance   |
| IB/0013/G             | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 09/07/2019   | n/a        |             |                                     |

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                             |            |            |                        |                                                                |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------|
| IB/0012/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                                        | 21/06/2019 | n/a        |                        |                                                                |
| PSUSA/10668 /201811 | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/06/2019 | n/a        |                        | PRAC Recommendation - maintenance                              |
| IB/0011             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                | 11/04/2019 | 23/01/2020 | SmPC                   |                                                                |
| II/0002             | Extension of Indication to include routine prophylaxis of bleeding episodes in patients with severe haemophilia A (congenital factor VIII deficiency, FVIII<1 %) without FVIII activity; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated with efficacy and safety information of the pivotal trials. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor corrections and clarity to sections 4.4, 4.5 and 4.6 of the SmPC. | 31/01/2019 | 11/03/2019 | SmPC, Labelling and PL | Please refer to Scientific Discussion Hemlibra-H-C-4406-II- 02 |

<div style=\"page-break-after: always\"></div>

|                     | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                      |            |            |                        |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10668 /201805 | Periodic Safety Update EU Single assessment - emicizumab                                                                                                                            | 13/12/2018 | 14/02/2019 | SmPC                   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10668/201805. |
| IB/0008             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data              | 25/10/2018 | n/a        |                        |                                                                                                                                            |
| IB/0007             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol | 22/10/2018 | 14/02/2019 | SmPC                   |                                                                                                                                            |
| IB/0005             | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking | 23/08/2018 | 14/02/2019 | SmPC, Labelling and PL |                                                                                                                                            |
| N/0006              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                    | 09/08/2018 | 14/02/2019 | PL                     |                                                                                                                                            |
| IB/0003/G           | This was an application for a group of variations. B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation              | 07/06/2018 | n/a        |                        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|        | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product   |            |            |       |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------|
| T/0001 | Transfer of Marketing Authorisation                                                                                                            | 16/04/2018 | 30/04/2018 | SmPC, |